CoChat

Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis

Open access

The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index; 12 of the 25 sources its claims cite were checked for support.

Abstract

Context: Although some patients with hypothyroidism prefer combination therapy with liothyronine (LT3) and levothyroxine (LT4), the safety of LT3 remains unresolved. Objective: We undertook a multisource systematic review and meta-analysis of LT3 safety. Data Sources: We searched PubMed for articles relating to death, adverse events (AEs), and cardiovascular outcomes in LT3 users. We also searched AEs data in the UK Yellow Card scheme and US Food and Drug Administration Adverse Reporting System (FAERS). Data Extraction: Data was extracted independently by 2 reviewers. Out of 1814 articles identified, 52 studies were selected, comprising 21 randomized controlled trials (RCTs), 4 cohort studies, and 27 case reports. Meta-analyses were conducted for adverse outcomes in RCTs and cohort studies of combination vs monotherapy. Data Synthesis: LT3-related AEs were only reported with unregulated LT3 use or pharmacy compounding errors. LT3 and LT4 showed similar adverse severity profiles in the Yellow Card scheme. Disproportionality analysis in the FAERS database showed no increased LT3 safety signals. A meta-analysis of RCTs (n = 2128) showed a similar AEs risk for combination vs monotherapy [relative risk (RR) 1.22, 95% confidence interval (CI) 0.66-2.25]. A cohort study meta-analysis (LT3 vs LT4-only users, n = 630 254) showed no increased risk of atrial fibrillation (RR 1.10, 95% CI 0.74-1.63), heart failure (RR 1.54, 95% CI 0.95-2.47), or strokes (RR 0.86, 95% CI 0.11-6.75), but reduced mortality risk was observed for LT3 (RR 0.70, 95% CI 0.62-0.78). Conclusion: Our findings are reassuring that regulated LT3 use is not associated with the risk of death or serious AEs. More studies are needed to supplement existing data.

Overview

CoChat Summary

TL;DR

This multisource systematic review and meta-analysis found that regulated liothyronine (LT3) use was not associated with increased risk of death or serious adverse events. Serious harms were almost exclusively linked to unregulated LT3 use or pharmacy compounding errors.

Key findings

  • Across 52 included studies (21 RCTs, 4 cohort studies, 27 case reports), serious LT3-related adverse events occurred mainly with compounding errors (10 cases) or unlicensed use for bodybuilding, weight loss, or fatigue (14 cases); no adverse event was reported in patients with hypothyroidism receiving supervised standard LT3 doses.
  • Meta-analysis of RCTs (n = 2128) showed similar adverse-event risk for combination LT3/LT4 vs LT4 monotherapy: RR 1.22, 95% CI 0.66-2.25; only the high-dose Smith 1970 trial reported more adverse events in the combination arm.
  • Cohort meta-analysis (LT3 vs LT4-only users, n = 630 254) showed no increased risk of atrial fibrillation (RR 1.10, 95% CI 0.74-1.63), heart failure (RR 1.54, 95% CI 0.95-2.47), or strokes (RR 0.86, 95% CI 0.11-6.75), but reduced all-cause mortality for LT3 (RR 0.70, 95% CI 0.62-0.78).
  • Pharmacovigilance analyses found similar adverse-event severity profiles for LT3 and LT4 in the UK Yellow Card scheme, and no increased LT3 safety signal in FAERS for serious adverse events or deaths; LT4 showed an increased serious-adverse-event reporting signal (ROR 1.45, 95% CI 1.42-1.47).

Methods

  • Systematic review of PubMed from inception to October 2024, plus ClinicalTrials.gov, ISRCTN, reference lists, UK Yellow Card scheme (1967-2024), and US FAERS (1968-2024); two reviewers extracted data independently.
  • Included case reports/series of death or serious adverse reactions on LT3, observational studies of death/cardiovascular outcomes/severe adverse events in LT3 vs LT4 users, and RCTs of combination therapy vs LT4 monotherapy reporting adverse events; 1814 articles identified, 52 selected.
  • Random-effects meta-analyses using restricted maximum likelihood for RCT adverse-event withdrawals and cohort outcomes; disproportionality analysis in FAERS using reporting odds ratios, proportional reporting ratios, and information components; cohort quality assessed with Newcastle-Ottawa Scale.

Limitations

  • The paper states that pharmacovigilance databases rely on voluntary reports and are subject to underreporting, symptoms may be subjective, LT3 reporting may be affected by notoriety bias, and disproportionality analyses indicate safety signals rather than causality.
  • The paper states that RCTs were often underpowered for adverse-event analysis, had short follow-up, and may be biased by underlying diagnoses and cardiovascular risk; several RCTs were excluded for not reporting adverse-event incidence, and cohort studies were heterogeneous with only 2 to 3 studies per outcome.
  • The paper notes that the reduced mortality finding should be interpreted cautiously because it may reflect unexplored selection factors, and the heart failure signal was driven by a Korean cohort with high thyroid cancer prevalence and possible TSH-suppressive dosing.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/clinem/dgaf449

Cites

75 of 76 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Flow chart for study inclusions.
Figure 1. Flow chart for study inclusions.CC BY · PubMed Central
Figure 2. Meta-analysis of withdrawals from randomized controlled trials due to adverse effects. Abbreviation: REML, restricted maximum likelihood.
Figure 2. Meta-analysis of withdrawals from randomized controlled trials due to adverse effects. Abbreviation: REML, restricted maximum likelihood.CC BY · PubMed Central
Figure 3. Meta-analysis of cohort studies. Abbreviations: REML, restricted maximum likelihood.
Figure 3. Meta-analysis of cohort studies. Abbreviations: REML, restricted maximum likelihood.CC BY · PubMed Central

Verification

Claims the paper makes

12 Valid · 0 Not valid · 8 Not checked · 51 Own results and interpretations

39 more claims · 1 with their cited sources checked

Create a free account to see all 71 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 11
  • It may state two separate claims as one. 20
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 8 · the rest aren’t loaded

3 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 76 references

Research works printed but not linked: 1

  1. De La Calzada-Jeanlouie, 2011, A case of thyrotoxicosis due to a compounding error, Clin Toxicol, 49, 553

Cited by

See all 11

Metadata

Authors
Bahl, S., Taylor, P. N., Premawardhana, L. D., Stedman, M., Heald, A., Dayan, C. M., & Okosieme, O. E.
Affiliations
  • Cardiff University (GB)
  • Res Consortium , Andover SP10 5RG ,
  • Manchester Academic Health Science Centre (GB)
  • Cwm Taf University Health Board (GB)
Corresponding author
Bahl, Suhani
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2025-08-08
Volume
110
Issue
11
Pages
3278-3288
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4413105622
Cited by
11
References
71
Citations by year
2026: 9 · 2025: 2
FWCI
1.48
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
Keywords
liothyronine, levothyroxine, hypothyroidism, drug safety, adverse events, mortality, atrial fibrillation, heart failure, stroke, combination thyroid hormone therapy, adverse drug reaction reporting, Yellow Card Scheme, FDA Adverse Event Reporting System
MeSH terms
Drug Therapy, Combination, Humans, Hypothyroidism, Thyroxine, Triiodothyronine, Randomized Controlled Trials as Topic, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1210/clinem/dgaf449
The paper
Bahl, S., Taylor, P. N., Premawardhana, L. D., Stedman, M., Heald, A., Dayan, C. M., & Okosieme, O. E. (2025). Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf449

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.